A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism
Abstract Background Secondary hyperparathyroidism may lead to increased cardiovascular risk. The use of cinacalcet may improve bone and cardiovascular health with improved parathormone (PTH) and phosphate control. Methods This is an open-label prospective randomised controlled trial to compare progr...
Main Authors: | Helen Eddington, Rajkumar Chinnadurai, Helen Alderson, Sara T. Ibrahim, Constantina Chrysochou, Darren Green, Ibi Erekosima, Alastair Hutchison, Abdalla Bubtana, Janet Hegarty, Philip A. Kalra |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-03-01
|
Series: | BMC Nephrology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12882-021-02312-2 |
Similar Items
-
Efficacy and Safety of Etelcalcetide in Hemodialysis Patients with Moderate to Severe Secondary Hyperparathyroidism
by: Paola Monciino, et al.
Published: (2022-09-01) -
Effect of switching from cinacalcet to etelcalcetide on secondary hyperparathyroidism in patients undergoing hemodialysis: an ESCORT trial
by: Yuka Kurokawa, et al.
Published: (2020-12-01) -
A single-centre retrospective analysis of cinacalcet therapy in primary hyperparathyroidism
by: Daniel Bell, et al.
Published: (2021-11-01) -
Recomendaciones de la Sociedad Española de Nefrología para el manejo de las alteraciones del metabolismo óseo-mineral en los pacientes con enfermedad renal crónica: 2021 (SEN-MM)
by: José-Vicente Torregrosa, et al.
Published: (2022-12-01) -
Hypoparathyroidism versus hyperparathyroidism in pediatric dialysis patients; a single center study
by: Mitra Naseri
Published: (2017-10-01)